Health Canada has allowed the firm to bypass a requirement that tests be authorized for non-professional use prior to self-test authorization.

Last week, readers were most interested in a story about Diasorin's submission to FDA for its POC testing instrument.

Investigators compared risk prediction using PathomIQ's platform to molecular test results, evaluating its ability to predict biochemical recurrence in high-risk patients.

The Tulane team has developed a handful of other assays for TB detection, including a mass spec test for paucibacillary TB ...

Broader macroeconomic uncertainty has resulted in continued cautiousness for both investors and acquirers in the in vitro ...

NEW YORK – With the recent completion of a multisite study in Europe and the opening of a lab in Tennessee, Glasgow, Scotland-based liquid biopsy developer Dxcover plans to launch its infrared ...

A lab owner, marketing firm owner, and doctor have been sentenced to between 13 months and five years in prison for their roles in a multimillion-dollar lab fraud scheme.

Lund, Sweden-based Qlucore aims to have bladder cancer and AML tests available for clinical use in Europe by 2027.

NEW YORK — Canadian diagnostics developer Nanostics said Thursday that it has received a C$3.8 million (US$2.8 million) grant from Genome Canada and Genome Alberta to boost the adoption of its ...